National Institute of Allergy and Infectious Diseases (NIAID): Dengue trials
The registry lists 36 Dengue studies with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor. 1 are open to participants now and 3 have results posted.
Phase 1 29Phase 2 3No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus InfectionRecruitingNCT07706686Phase 1
- An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 ChallengeCompletedNCT05048875Phase 2Results posted
- Sylvatic Transmission of Zika, Dengue, and Chikungunya Viruses in Thailand and CambodiaCompletedNCT04434846Results posted
- Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, BangladeshCompletedNCT02678455Phase 2Results posted
- A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue)CompletedNCT04514107Not applicable
- Investigating Vector-Borne Determinants of Aedes Transmitted Arboviral Infections in Cambodia: An Observational Longitudinal Cohort Study in ChildrenCompletedNCT03534245
- Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 ChallengeCompletedNCT03416036Phase 1
- Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of AgeCompletedNCT02879266Phase 1
- Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30CompletedNCT02873260Phase 1
- Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus VaccineCompletedNCT02684383Phase 1
- Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)CompletedNCT02450838Phase 1
- Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2CompletedNCT02433652Phase 1
- Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy AdultsCompletedNCT02392325Phase 1
- Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and Children in ThailandCompletedNCT02332733Phase 2
- Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy AdultsCompletedNCT02317900Phase 1
- Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy AdultsCompletedNCT02021968Phase 1
- Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy AdultsCompletedNCT01931176Phase 1
- Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months ApartCompletedNCT01782300Phase 1
- Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus VaccineCompletedNCT01506570Phase 1
- Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus VaccineCompletedNCT01436422Phase 1
- Tetravalent Chimeric Dengue Vaccine TrialCompletedNCT01110551Phase 1
- Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 VaccineCompletedNCT01084291Phase 1
- Safety and Immune Response to an Investigational Dengue Type 2 VaccineCompletedNCT01073306Phase 1
- Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus VaccineCompletedNCT01072786Phase 1
- Safety and Immune Response to Two Doses of rDEN2/4delta30 Dengue VaccineCompletedNCT00920517Phase 1
- Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue VirusCompletedNCT00919178Phase 1
- Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy AdultsCompletedNCT00831012Phase 1
- Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy AdultsCompletedNCT00712803Phase 1
- Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus VaccineCompletedNCT00473135Phase 1
- Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue VirusCompletedNCT00458120Phase 1
- Prospective Study of Infant DengueStatus unknownNCT00377754
- Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy AdultsCompletedNCT00375726Phase 1
- Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-4995) in Healthy AdultsCompletedNCT00322946Phase 1
- Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy AdultsCompletedNCT00270699Phase 1
- Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy AdultsCompletedNCT00094705Phase 1
- Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy AdultsCompletedNCT00089908Phase 1